Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.